Cedelizumab
From Wikipedia, the free encyclopedia
Cedelizumab is a monoclonal antibody acting on the immune system.[1] Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.[2]
[edit] References
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
|
|
|
Unsorted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immune system ("-l(i[m])-") |
|
Human ("-limu-")
|
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
| Interleukin ("-k(i[n])-") |
|
Human ("-kinu-")
|
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
(what is this?) (verify)
